Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Partially Randomized, Open-Label Study of Visilizumab in Patients With Severe Ulcerative Colitis Refractory to Intravenous Corticosteroids

NCT00267306 is registered in ClinicalTrials.gov with Facet Biotech as lead sponsor.

NCT NCT00267306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00267306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Partially Randomized, Open-Label Study of Visilizumab in Patients With Severe Ulcerative Colitis Refractory to Intravenous Corticosteroids
Lead sponsor
Facet Biotech
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2004
Completion date
December 31, 2006
Enrollment
144
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

severe ulcerative colitis